Related Experiment Video
Updated: Feb 21, 2026
06:47
Microfluidics in Assessing Platelet Function
Published on: November 8, 2024
1.7K
Impact of levosimendan on platelet function
Joanna Sikora1, Krzysztof Pstrągowski2, Natalia Skibińska2
1Department of Pharmacology and Therapy, Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz, Poland.
Thrombosis Research
|October 9, 2017
Summary
Levosimendan, used for severe heart failure, has a dual action affecting heart muscle contractility and blood vessel dilation. This review examines its impact on platelet function, with mixed findings in current research.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Levosimendan is a drug developed for severe heart failure.
- Its hemodynamic effects stem from increased myocardial contractility and vasodilation.
- Potential phosphodiesterase III inhibition may contribute to its action.
Purpose of the Study:
- To systematically review and critically discuss the impact of levosimendan on platelet function.
- To consolidate current knowledge from experimental, observational, and clinical studies.
Main Methods:
- Systematic review of existing literature.
- Critical analysis of experimental, observational, and randomized clinical studies.
Main Results:
- Existing reports on levosimendan's effect on platelet function are contradictory, indirect, or inconclusive.
- Further investigation is needed to clarify its anti-aggregatory effects.
Conclusions:
- The precise impact of levosimendan on platelet aggregation remains unclear.
- Further research is warranted to elucidate levosimendan's effects on platelet function.
More Related Videos
Related Concept Videos
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
1.4K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.4K
01:22Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
3.7K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
3.7K
01:22Formation of the Platelet Plug
9.9K
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
9.9K
01:26Heart Failure Drugs: Inotropic Agents
1.6K
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
1.6K
01:12Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
2.7K
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
2.7K
01:20Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
2.3K
Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
2.3K